Turn Therapeutics Announces Human Trial Data for COVID-19 Early Intervention Candidate

LOS ANGELES--(BUSINESS WIRE)-- #Coronavirus--Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the results of its Phase 2B, placebo controlled trial of Hexagen Antimicrobial Ointment in treating mild to moderate infected COVID-19 patients. This double-blinded study enrolled 80 people across three sites in Panama...

Click to view original post